Results for tag: "KRAS"

KRAS is a family of proteins that are involved in the regulation of cell growth and survival. In oncology, KRAS is a key target for drug development, as mutations in the KRAS gene are associated with a variety of cancers, including colorectal, pancreatic, and lung cancer. KRAS inhibitors are a type of targeted therapy that works by blocking the activity of mutated KRAS proteins, thus preventing cancer cells from growing and spreading. Currently, there are several companies developing KRAS inhibitors, including Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, and Pfizer. These companies are working to develop drugs that can target specific KRAS mutations, as well as combination therapies that can be used in combination with other treatments. Additionally, there are several clinical trials underway to evaluate the efficacy of KRAS inhibitors in treating various types of cancer. Show Less Read more